881402-27-3

Basic information

• Product Name: tert-butyl (5-bromothiazol-2-yl)(4-methoxybenzyl)carbamate
• Synonyms: tert-butyl (5-bromothiazol-2-yl)(4-methoxybenzyl)carbamate
• CAS NO: 881402-27-3
• Molecular Weight: 399.308
• Mol File: 881402-27-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: tert-butyl (5-bromothiazol-2-yl)(4-methoxybenzyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (5-bromothiazol-2-yl)(4-methoxybenzyl)carbamate(881402-27-3)
• EPA Substance Registry System: tert-butyl (5-bromothiazol-2-yl)(4-methoxybenzyl)carbamate(881402-27-3)

Safety Data

• Hazardous Substances Data: 881402-27-3(Hazardous Substances Data)

Upstream product

• 105-13-5 4-Methoxybenzyl alcohol 
• 405939-39-1 tert-butyl 5-bromothiazol-2-ylcarbamate 
• 824-94-2 p-methoxybenzyl chloride 

Relevant articles and documents

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

Preparation of 3,4-Substituted-5-Aminopyrazoles and 4-Substituted-2-Aminothiazoles

3,4-Substituted-5-aminopyrazoles and 4-substituted-2-aminothiazoles are frequently used intermediates in medicinal chemistry and drug discovery projects. We report an expedient flexible synthesis of 3,4-substituted-5-aminopyrazoles (35 examples), based on palladium-mediated α-arylation of β-ketonitriles with aryl bromides. A library of 4-substituted-2-aminothiazoles (21 examples) was assembled by a sequence employing Suzuki coupling of newly prepared, properly protected pinacol ester and MIDA ester of 4-boronic acid-2-aminothiazole with (hetero)aryl halides.

NOVEL COMPOUNDS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.